Through a multidisciplinary team of industry, regulatory, and scientific specialists, Gershon Capital helps organizations to prevent and resolve compliance problems and to develop efficient and effective strategies for the submission and approval of drugs, biologics, and devices.
Gershon Capital assists healthcare and life science companies achieve their business objectives through integrated reimbursement, clinical research, regulatory affairs, and marketing strategies. Through the integration of these key functional areas, we have the ability to assist our clients in the full array of activities involved in successfully moving a product from concept to commercialization. Strategic thinking and integrated operations result in approved products that rest on a foundation of strong clinical claims and data to support optimal reimbursement and impact market share.
The company deploys only highly experienced consultants who consistently deliver top-quality results for a diverse base of global clients—including pharmaceutical biologic, biotechnology, medical device, and dietary supplement companies and the law firms that serve them.
For additional information, contact:
Patty Telgener, Director of Pricing and Reimbursement, Gershon Capital & Cie
Roy Sturgeon, Ph.D., Director of FDA Regulatory Affairs and Compliance, Gershon Capital & Cie